The second drug approved was neratinib, which received the indication for the extended adjuvant treatment of early stage hormone receptor-positive and HER2-positive breast cancer who completed adjuvant trastuzumab-based therapy less than one year before, based on the ExteNET trial results. This evidence concerns the gene NR4A1 and breast carcinoma.